Search
Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.
News
18 April 2024
While economic factors, including the high cost of capital, continue to keep our clients up at night, we also see signs of optimism in 2024. Against this fiscal backdrop, significant recent ...
News
02 April 2024
The Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and...
Insights and Analysis
29 March 2024
Advancements in medical technology make healthcare and radiopharmaceutical companies attractive investment prospects. And we are seeing this interest in real time. However, acquiring...
News
24 March 2024
On March 6, 2024, the U.S. Securities and Exchange Commission adopted its highly anticipated rules requiring climate-related disclosures.
News
12 March 2024
The 2024 American Bar Association White Collar Crime conference delivered crucial insights from artificial intelligence’s tantalizing promise to its looming threats, a focus on...
News
29 February 2024
Although upfront fees, milestones and royalties often take the spotlight in deal announcements in the life sciences sector, there exist numerous other cost allocation principles within...
News
21 February 2024
Speaking at the J.P. Morgan Healthcare Conference this year, Hogan Lovells life sciences regulatory partners Lowell Zeta and Blake Wilson, were joined by Greenleaf Health’s Kalah...
News
21 February 2024
Last week, the U.S. Food and Drug Administration (FDA) published a draft guidance on the use of data monitoring committees (DMCs) in clinical trials entitled “Use of Data Monitoring...
News
17 February 2024
The U.S. Food and Drug Administration (FDA) continues its efforts to include diverse participants in clinical research with a newly-published revision to its draft guidance document...
